151 results about "Traitement adjuvant" patented technology

Predicting response to adjuvant therapy or predicting disease progression in breast cancer is realized by (1) first obtaining a breast cancer test sample from a subject; (2) second obtaining clinicopathological data from said breast cancer test sample; (3) analyzing the obtained breast cancer test sample for presence or amount of (a) one or more molecular markers of hormone receptor status, one or more growth factor receptor markers, (b) one or more tumor suppression / apoptosis molecular markers; and (c) one or more additional molecular markers both proteomic and non-proteomic that are indicative of breast cancer disease processes; and then (4) correlating (a) the presence or amount of said molecular markers and, with (b) clinicopathological data from said tissue sample other than the molecular markers of breast cancer disease processes. A kit of (1) a panel of antibodies; (2) one or more gene amplification assays; (3) first reagents to assist said antibodies with binding to tumor samples; (4) second reagents to assist in determining gene amplification; permits, when applied to a breast cancer patient's tumor tissue sample, (A) permits observation, and determination, of a numerical level of expression of each individual antibody, and gene amplification; whereupon (B) a computer algorithm, residing on a computer can calculate a prediction of treatment outcome for a specific treatment for breast cancer, or future risk of breast cancer progression.

The invention discloses a preparation method for the dendritic cell (DC) of an umbilical cord blood source and a dendritic cell (DC) vaccine, which relates to a preparation method for the dendritic cell. According to the method, various cell factors are adopted to induce DC obtained by umbilical cord blood separation, and then the DC is stimulated by a tumor specific antigen so as to improve the specific antigen presentation capability of the DC; and a stem cell growth factor and Flt3-L are added into a cell culture medium so as to effectively accelerate a hematopoietic cell in the umbilical cord blood to induce and proliferate to an immune cell. The DC vaccine prepared with the method has the specific antigen presentation capability, can be combined with a CIK (cytokine induced killer) cell to mutually treat the malignant tumor when being used as a tumor immunotherapy product, and is used as an important adjuvant therapy after operations and chemoradiotherapy. Recurrence and metastasis after the operations can be effectively prevented, and toxic and side effects caused by the chemoradiotherapy on patients are lowered so as to improve the treatment effect.

The invention relates to a pseudomonas aeruginosa mutant strain genetic engineering mutant strain, in particular to a pseudomonas aeruginosa mutant strain exotoxin A attenuated strain, and further relates to a preparation method of the mutant strain and application of the mutant strain or the attenuated strain in preparing vaccines or adjuvant therapy drugs.

The invention discloses cell inactivated vaccine which simultaneously contains porcine circovirus epitopes and goose circovirus epitopes. The cell inactivated vaccine is prepared by the method including screening high-pathogenicity strains from porcine circoviruses; selecting a plurality of virus epitopes; connecting the epitopes with one another; then inserting the connected epitopes into genomes of goose circoviruses to proliferate; and adding Freund adjuvants to formaldehyde for inactivation so as to obtain the cell inactivated vaccine. The invention simultaneously discloses an egg yolk antibody prepared from the cell inactivated vaccine, injection and freeze-dried powder containing the egg yolk antibody. Genes of the porcine circovirus are inserted into the genomes of the goose circoviruses, the immunogenicity of the goose circoviruses is strengthened, immune systems of goose bodies are excited, so that the titer of generated antibodies is higher than that of egg yolk antibodies generated by porcine circovirus vaccine used singularly, a clinical application effect is good, and generated circovirus antibodies have an auxiliary treatment effect for porcine circovirus diseases.

The invention discloses a method for preparing ice cream by adopting camel milk. According to the method disclosed by the invention, the camel milk or camel milk powder is used as the main raw material, then the raw materials such as honey, poria cocos, Chinese yam and sodium caseinate are added, a special raw material extraction technology is adopted, and the prepared ice cream is low in energy, high in protein content and low in fat content; meanwhile, due to the combined action of all raw materials, an adjuvant therapy effect on hyperlipidemia, hypertension, chronic pharyngitis, prostate disease, fatty liver and tumor radio-chemotherapy is obtained, congestive heart failure can also be relieved, coughs can be relieved, the kidney can be protected, negative conversion of hepatitis B is facilitated, and the immunity can be greatly enhanced.

Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and / or expression of p38 MAPK and / or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

The invention relates to a macromolecular hydrophilic gel and a preparation method and application thereof. The gel is made of Carbomer mixed with purified water, glycerinum and polysorbate, the pH value is adjusted by using sodium hydroxide solution, and the gel with negative electricity is prepared. The macromolecular hydrophilic gel has irregular bubbles, no stimulation and no other macroscopicexogenous impurities, and is transparent, in a viscous colloid shape and free from extraneous odor, the pH value is equal to 6.30-9.37, the dynamic viscosity is 5000-7000 mPa s, the microbial contentis 10 cfu / g, the total effective rate for allergic rhinitis patients in a clinical test can reach about 90%, and the effective rate of an on-sale congeneric product Mobijing as a control group is nomore than 70%; it is shown that compared with the congeneric product, the macromolecular hydrophilic gel can cure allergic rhinitis better, and has a good preventive and adjuvant therapeutic effects on the allergic rhinitis.

The invention relates to a method for establishing a prediction model for survival benefit of a gallbladder cancer patient after chemoradiotherapy. The method comprises the steps of acquiring clinical and pathological data of the gallbladder cancer patient; dividing the acquired data into a plurality of groups of data according to the TNM stages, and respectively judging whether the patient in each stage is benefited from adjuvant therapy or not; dividing the data corresponding to the TNM stages into a modeling group and an internal verification group; analyzing the prediction capability of clinical and pathological variables of the modeling group data on the total survival time OS through a single-factor COX risk scale model, and screening risk factors which significantly influence the total survival time OS of the patient in the modeling group; incorporating the screened risk factors into a multi-factor COX risk scale model for analysis, and screening out influence variables significantly influencing the total survival time OS of the patient; according to the obtained influence variables, drawing a column graph used for predicting the total survival time OS, and obtaining a prediction model; and verifying the model. Compared with the prior art, the method has the advantages of providing credible prediction and analysis results for the GBC patient, being simple and convenient to operate and the like.

The invention discloses an early NSCLC prognosis prediction system, which comprises a main effect identification module, an interaction identification module, a survival time prediction module and a high-dimensional population discrimination module, and can improve the model prediction precision from the perspective of cross-omics by establishing a sample database and molecular biomarkers-methylation and gene expression. Different from a traditional biomarker, the system is stable and minimally invasive, the sensitivity and specificity of prognosis prediction are greatly improved, the main effect, GxE and GxG interaction effects are integrated, an early-stage NSCLC survival prediction model which is high in prediction precision and has strict multi-stage independent crowd verification is constructed, the defect that an existing model is poor in prediction effect is overcome, and a high-risk crowd discrimination module is combined. People with different risks are discriminated, diseaseprognosis is evaluated scientifically and accurately, and clinicians are helped to make clinical decisions or guide adjuvant therapy, early intervention and early benefit.

The invention relates to a blood filtering and dialyzing system capable of filtering and separating CTCs of a human body from circulation blood of the human body. The blood filtering and dialyzing system serves as an adjuvant therapy device and is suitable for breast cancer patients with the positive CTCs. The blood filtering and dialyzing system is characterized in that in a pipe channel of an existing blood filtering and dialyzing device, a filter composed of biological membranes 8 micrometers in hole diameter is additionally arranged. The filter is a cylinder and taper double-layer barrel, and the blood dialyzing instrument artery end is communicated with an inner layer, wherein the inlet radius is r, and the inner layer is composed of biological membranes 8 micrometers in hole diameter; the blood dialyzing instrument vein end is communicated with an outer layer, and the outer layer is made of medical plastic. According to the filter, the heights of a cylinder in the inner layer and a cylinder in the outer layer are equal, the length is controllable in the scope ranging from 10 cm to 20 cm, the inner diameter is 4.472 r, the outer diameter is 4.48 r, the height of an inner taper is 4.472 r, the height of an outer tapper is 4.48 r, and the membrane hole distribution density is 100000 / cm<2>.

Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID NO:30); ARTAGLLAPMDY (SEQ ID NO:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID NO:32) or VRDL YGDYVGRY A Y (SEQ ID NO:48).